New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference

STOCKHOLM, Oct. 30, 2024 /PRNewswire/ — Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still’s disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset still’s disease…